Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
LY2183240
Cat. No.:
OB0225LY-0333
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
LY2183240 is a selectively targeted glucocorticoid pathway-based drug for autoimmune diseases.
Synonym:
874902-19-9; LY-2183240; LY 2183240; 5-Biphenyl-4-ylmethyl-tetrazole-1-carboxylic acid dimethylamide; N, N-Dimethyl-5-[(4-phenylphenyl)methyl]tetrazole-1-carboxamide; 5-([1,1'-Biphenyl]-4-ylmethyl)-N, N-dimethyl-1H-tetrazole-1-carboxamide; 1H-Tetrazole-1-carboxamide, 5-((1,1'-biphenyl)-4-ylmethyl)-N, N-dimethyl-
CAS No.:
874902-19-9
Compound CID:
11507802
Formula:
C17H17N5O
Formula Weight:
307.35
Specification
Relative Density:
1.22 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
LY2183240 can be used for autoimmune and inflammatory disease research or play an important role in the development of new drugs.
Library Information
Targets:
Metabolic enzymes
Receptors:
FAAH
Pathways:
Autophagy; Metabolism; Neuronal signaling
Plate Number:
AOCL-5
Plate Location:
c7
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
65 mg/mL; 211.49 mM
